Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
How has the gonadotropin-releasing hormone (gnrh) agonist market grown over the years?
The market size of the agonist for gonadotropin-releasing hormone (GnRH) has experienced consistent expansion in the recent past. Its growth is projected to rise from $4.1 billion in 2024 to $4.23 billion in 2025, reflecting a compound annual growth rate (CAGR) of 3.2%. The past period’s growth can be credited to increased awareness and diagnoses of hormonal disorders, a surge in the prevalence of diseases related to hormones, a rise in prostate cancer cases, enhanced understanding of hormone therapy, and amplified demand for prolonged safety and efficacy.
What Is the forecasted market size and growth rate for the gonadotropin-releasing hormone (gnrh) agonist market?
The market size for the gonadotropin-releasing hormone (GnRH) agonist is projected to experience consistent growth in the forthcoming years. An anticipated surge to $4.72 billion by 2029, with a compound annual growth rate (CAGR) of 2.8%, is expected. Factors contributing to this growth during the forecast period include growing awareness and early detection, increased expenditure in healthcare, rising use in fertility procedures, a growing desire for personalized medicine, and an increase in funds for research. Notable trends for the forecast period encompass improvements in drug delivery systems, advancements in both oncology and reproductive medicine, a surging demand for hormone therapy alternatives, growing research and development, and the emergence of long-acting formulations.
Get your gonadotropin-releasing hormone (gnrh) agonist market report here!
What are the major factors driving growth in the gonadotropin-releasing hormone (gnrh) agonist market?
The escalating incidence of diseases linked to hormonal imbalances is predicted to fuel the expansion of the gonadotropin-releasing hormone (GnRH) agonist market. Medical conditions instigated by discrepancies or malfunctions in the endocrine system, the producer and regulator of hormones, are categorized as hormone-related disorders. These include ailments like diabetes, hyperthyroidism, and prostate cancer. Environmental factors, obesity, metabolic syndrome, genetic predispositions, and an ageing population contribute to the increasing prevalence of such disorders. Gonadotropin-releasing hormone (GnRH) agonists effectively regulate hormone levels and present a customized solution for issues stemming from hormonal imbalances and associated diseases. As an illustration, the Australian Bureau of Statistics announced that approximately one in twenty people, or 5.3% (around 1.3 million individuals), were afflicted with diabetes in 2022. The occurrence of diabetes was alike among both sexes, with male and female rates standing at 5.8% and 4.9% respectively. Moreover, diabetes was the seventh most common cause of death in Australia, causing 6,050 deaths in that year. Hence, the escalating incidence of hormone-related diseases is leading to the expansion of the gonadotropin-releasing hormone (GnRH) agonist market.
What key areas define the segmentation of the global gonadotropin-releasing hormone (gnrh) agonist Market?
The gonadotropin-releasing hormone (GnRH) agonist market covered in this report is segmented –
1) By Type: Leuprorelin, Goserelin, Taltirelin, Histrelin, Other Types
2) By Formulation: Injectable, Implants, Oral, Nasal Sprays
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
4) By Application: Prostate Cancer, Breast Cancer, Endometriosis, Uterine Fibroids, Precocious Puberty, Fertility Treatment, Other Applications
5) By End-User: Hospital, Specialty Clinics, Ambulatory Surgical Centers (ASCs), Other End-Users
Subsegments:
1) By Leuprorelin: Injectable Leuprorelin, Implantable Leuprorelin
2) By Goserelin: Goserelin Injection, Goserelin Implant
3) By Taltirelin: Injectable Taltirelin, Oral Taltirelin
4) By Histrelin: Histrelin Implant, Histrelin Injection
5) By Other Type: Triptorelin, Buserelin, Nafarelin
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18814&type=smp
What are the top market players propelling the growth of the gonadotropin-releasing hormone (gnrh) agonist industry?
Major companies operating in the gonadotropin-releasing hormone (GnRH) agonist market are Pfizer Inc., AbbVie Inc., Takeda Pharmaceutical Company Limited, Sandoz Group AG, Ipsen Pharma, Aurobindo Pharma Limited, Cipla Limited, Dr Reddy’s Laboratories Ltd., Intas Pharmaceuticals Ltd., Ferring Pharmaceuticals, Amneal Pharmaceuticals Inc., Endo International plc, Lupin Limited, Gland Pharma Limited, Glenmark Pharmaceuticals Ltd., Zydus Lifesciences Limited, Bachem Holding AG, Tolmar Pharmaceuticals Inc., Debiopharm Group, Sun Pharmaceutical Industries Ltd.
What are the key trends shaping the future of the gonadotropin-releasing hormone (gnrh) agonist market?
Big players in the gonadotropin-releasing hormone (GnRH) agonist market are working to create innovative androgen deprivation therapy (ADT) drugs to improve the accuracy and potency of treatments for hormone-responsive malignancies. These ADT drugs, encompassing GnRH analogs, work by decreasing or eradicating androgen amounts to decelerate or stop the progression of hormone-sensitive cancers. For design, in January 2024, Zydus Lifesciences Limited, a pharmaceutical company based in India, unveiled Relugolix with the brand moniker Rexigo, making it the first and only daily oral therapy in India for testosterone reduction in advanced prostate cancer, thereby phasing out the need for injectable solutions. This easy-to-take oral option houses Relugolix, an internationally recognized active component for quick testosterone suppression. The Rexigo, which is 50% more economical than the existing injectable options for advanced prostate cancer in India, marks a significant stride in prostate cancer treatment, providing a secure, efficient, and patient-friendly alternative for both patients and medical practitioners.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18814
What regions are dominating the gonadotropin-releasing hormone (gnrh) agonist market growth?
North America was the largest region in the gonadotropin-releasing hormone (GnRH) agonist market in 2024. The regions covered in the gonadotropin-releasing hormone (GnRH) agonist market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Parathyroid Hormone Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/parathyroid-hormones-global-market-report
Follicle Stimulating Hormone Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/follicle-stimulating-hormone-global-market-report
Hormone Therapy Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/hormone-therapy-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
